Market revenue in 2023 | USD 292.5 million |
Market revenue in 2030 | USD 442.5 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 55.38% in 2023. Horizon Databook has segmented the Latin America biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
Latin American region captured 3.85% of the global biologics contract development market in 2019 and is anticipated to exhibit significant growth opportunities in the coming years. In Latin America, 80% of the population lives in metropolitan cities, and the three mega cities, Sao Paulo, Buenos Aires, and Mexico City, have large patient pools.
Although the regulatory timelines in Latin America are a drawback, the time saved in patient recruitment compensates for it. In addition to patient recruitment, retention is also very high due to good patient-physician relationship.
Lower costs, highly qualified investigators & medical personnel, and study coordinators with GCP compliant knowledge contribute to higher clinical trial success rate. Moreover, Argentina and Brazil are expected to witness lucrative growth in the CRO market due to the cost advantage they have over the developed economies, such as the U.S. and the European nations like Germany & others.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America biologics contract development market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account